Syndicated Research Report Diagnostics

RSV Diagnostics Market

Size, Share & Industry Analysis, By Type (Kits and Assays, Instruments, Other), By Application (Hospitals and Clinics, Clinical Laboratories, Other), By Testing Technology (Molecular NAAT, Rapid Antigen Immunoassay, Viral Culture and Other), By Care Setting (Hospital-Based, Outpatient and Urgent Care, Reference Laboratories, Public Health Surveillance), and Global Forecast, 2026-2034

Report ID 24LS-9340
Pages 88
Last Updated
Author 24LifeSciences Research Team
Industry Diagnostics
Starting from $995 USD

Market Overview

2026 Market SizeUSD 927.1 MnBase year
2027 EstimateUSD 1.0 BnEstimated year
2036 ForecastUSD 2.0 BnForecast value
CAGR8.0%2027–2036
Largest RegionNorth America2026

RSV Diagnostics Market Overview

The global RSV diagnostics market is valued at USD 927.1 million in 2026, estimated at USD 1.0 billion in 2027, and projected to reach USD 2.0 billion by 2036, reflecting an 8.0% CAGR during 2027–2036.

3.6 millionAnnual RSV-associated hospitalizations in children under five worldwideWHO, December 2025
100,000Estimated annual RSV-attributable deaths in children under fiveWHO, December 2025
20 minutesEstimated sample-to-result time for cobas Liat Flu A/B and RSVRoche Diagnostics
2026CDC updated clinical RSV diagnostic-testing guidanceCDC, February 2026

RSV diagnostics comprise rapid antigen tests, nucleic acid amplification assays, and the RSV-attributable component of multiplex respiratory panels. The market includes reagents, assay cartridges, specimen-processing consumables and the attributable share of diagnostic instrument revenue. It excludes vaccines, preventive monoclonal antibodies, clinical treatment, and the non-RSV portion of multipathogen testing revenue. Hospital laboratories, emergency departments and pediatric clinics purchase tests to distinguish RSV from influenza and other respiratory infections.

The World Health Organization estimates more than 3.6 million RSV-associated hospitalizations and about 100,000 deaths annually among children younger than five. Severe infection is concentrated among very young infants, older adults and people with underlying disease. Clinical symptoms overlap with other respiratory pathogens, so laboratory confirmation supports infection-control decisions, patient placement and surveillance. Seasonal surges create uneven purchasing patterns, requiring laboratories to balance cartridge availability against inventory expiry.

The CDC updated RSV diagnostic guidance in February 2026, describing molecular nucleic acid amplification tests as highly sensitive and antigen tests as generally less sensitive. Multiplex testing can identify RSV alongside influenza and SARS-CoV-2 when symptoms are indistinguishable. Molecular platforms are moving closer to patients, while lower-cost antigen products remain useful in suitable pediatric settings. Product indications, specimen types and age-specific sensitivity must be checked before choosing an assay.

Roche offers a cobas Liat influenza A/B and RSV molecular test with an about 20-minute workflow, while Cepheid markets Xpert Xpress Flu/RSV for rapid molecular differentiation. Abbott BinaxNOW RSV and QuidelOrtho Sofia RSV FIA illustrate the antigen-testing alternative. Competition increasingly depends on instrument placement, turnaround time, multiplex breadth, reimbursement, and the recurring cost of cartridges rather than solely on analytical sensitivity.

Source: WHO RSV fact sheet; CDC RSV diagnostics; Roche cobas Liat; Cepheid Xpert.

Key Takeaways: RSV Diagnostics Market

  • Base-year market size: RSV-specific diagnostic revenue is modeled at USD 927.1 million in 2026.
  • Forecast and CAGR: The market is estimated at USD 1.0 billion in 2027 and projected at USD 2.0 billion by 2036, an 8.0% CAGR.
  • Leading type: Kits and Assays represented an estimated ~74% of 2026 revenue, reflecting repeat purchases of diagnostic consumables.
  • Leading application: Hospitals and Clinics represented an estimated ~55% of 2026 revenue owing to acute-care testing and pediatric admissions.
  • Largest region: North America represented an estimated ~39% of 2026 revenue, supported by molecular test availability and established reimbursement.
  • Growth drivers: RSV burden, expanding multiplex workflows, diagnostic differentiation and respiratory surveillance support testing demand.
  • Competitive landscape: Abbott, Roche, Cepheid, QuidelOrtho, bioM - rieux, Hologic and other diagnostics suppliers compete across antigen and molecular methods.
  • Report coverage: The study analyzes type, application, testing technology and care setting across five regions for 2027–2036.

Report Scope & Market Segmentation

This study sizes RSV-specific diagnostic products and allocated RSV portions of multiplex respiratory testing, measured as global supplier revenue rather than patient spending or vaccine sales.

Report AttributeCoverage
Base Year2026
Estimated Year2027
Forecast Period2027–2036
Market MeasurementRevenue, USD million/billion
By TypeKits and Assays; Instruments; Other
By ApplicationHospitals and Clinics; Clinical Laboratories; Other
By Testing TechnologyMolecular NAAT; Rapid Antigen Immunoassay; Viral Culture and Other
By Care SettingHospital-Based; Outpatient and Urgent Care; Reference Laboratories; Public Health Surveillance
By RegionNorth America; Europe; Asia-Pacific; Latin America; Middle East & Africa
Selected CountriesUnited States; Canada; Germany; United Kingdom; China; Japan; India; Brazil; South Africa
Key Market PlayersAbbott Laboratories; bioM - rieux SA; F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Thermo Fisher Scientific Inc.; Danaher Corporation (Cepheid); QuidelOrtho Corporation; Sekisui Diagnostics; Hologic Inc.; DiaSorin (Luminex); Meridian Bioscience

Market Definition & Revenue Boundaries

Revenue covers RSV antigen assays, molecular tests, cartridges, and instruments attributable to RSV testing. Multiplex panels are allocated only their RSV-associated value rather than the entire panel price, avoiding double counting of influenza and SARS-CoV-2 markets. Vaccine sales, prophylactic antibodies and hospital treatment costs are excluded. The analytical boundary follows commercial diagnostic sales, not the epidemiological burden of infection.

The Type axis separates consumable Kits and Assays from Instruments and Other products. Application reflects the purchasing clinical customer; Testing Technology distinguishes molecular from antigen and legacy methods; Care Setting distinguishes the location of test delivery. Each dimension is a separate 100% partition of the same 2026 revenue base. Geographic estimates allocate manufacturer revenue to the end-market where testing is used.

RSV Diagnostics Market Dynamics

Drivers Impact Analysis*

Market DriversImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
Pediatric RSV disease burden and hospitalization testingHigh+3.10%HighHighHigh
Molecular multiplex respiratory panel adoptionHigh+2.80%HighHighHigh
Rapid point-of-care molecular workflowsMedium+1.80%MediumHighHigh
Expanded respiratory surveillance and clinical awarenessMedium+1.30%MediumMediumHigh
Others (installed instrument utilization and expanded assay menus)Low+0.70%LowMediumMedium

Restraints Impact Analysis*

Market RestraintsImpact RankCAGR Contribution (%)2027–20292030–20322033–2036
Antigen sensitivity limitations and confirmatory testingHigh-0.70%HighMediumMedium
Seasonal purchasing fluctuations and cartridge inventory riskMedium-0.60%HighMediumMedium
Others (cost and infrastructure barriers for molecular assays)Medium-0.40%MediumMediumLow

*CAGR contribution shows the percentage points each factor adds to or removes from the 8.0% CAGR for 2027–2036; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

High pediatric RSV hospitalization burden sustains diagnostic demand

WHO estimates 3.6 million RSV-associated hospitalizations annually in children under five. Testing is particularly important for infants with bronchiolitis and patients admitted during winter surges. Clinical differentiation from influenza and other respiratory pathogens supports cohorting and infection-control decisions. The scale of serious pediatric illness sustains recurring purchases of rapid assays and molecular cartridges, although the number of tests ordered depends on local clinical protocols and reimbursement rather than incidence alone. Hospital diagnostic procurement is also influenced by specimen collection and the availability of validated assays.

Multiplex molecular platforms expand RSV test utilization

CDC guidance updated on 27 April 2026 describes molecular multiplex tests capable of distinguishing influenza, SARS-CoV-2 and RSV. Overlapping clinical symptoms make pathogen differentiation useful in emergency departments and outpatient clinics. Multiplex cartridge platforms also simplify staff training and instrument procurement by consolidating testing across seasonal respiratory pathogens. Their growth raises the RSV-attributable share of respiratory diagnostic spending, although the market model allocates only the RSV portion of each panel to avoid counting other pathogens.

Point-of-care workflows reduce time to clinical decisions

Roche describes an about 20-minute sample-to-result workflow for cobas Liat influenza A/B and RSV. Cepheid reports RSV-positive results in as little as 20 minutes on Xpert Xpress Flu/RSV. Short turnaround enables rapid patient placement and supports testing in urgent-care environments with limited access to centralized laboratories. Instrument placement, staff workflow and cartridge availability can therefore matter as much as assay sensitivity when hospitals and clinics select diagnostic suppliers. Flexible instrument placement also helps laboratories respond to changing respiratory-virus seasons.

Lower antigen sensitivity can constrain adult testing

CDC states that RSV antigen tests are generally less sensitive than molecular NAAT assays. Age and specimen type materially influence clinical performance, making negative antigen results less reliable for some adults with lower viral loads. Laboratories may therefore confirm selected negative antigen findings with molecular methods, raising total testing cost and delaying definitive decisions. Antigen products retain a role where rapid low-cost testing is clinically appropriate, but sensitivity limitations favor molecular adoption in high-risk settings.

Seasonal surges complicate diagnostic inventory and staffing

CDC surveillance guidance identifies a typical United States RSV season beginning in autumn, peaking in winter and ending in spring. Suppliers must maintain cartridge inventory for short demand spikes without accumulating expired stock during lower-activity months. Hospitals may add shifts or redirect instruments to respiratory panels during peaks, while smaller clinics may reduce ordering outside the season. These fluctuations complicate forecasting and favor products with longer shelf lives, multipathogen menus and flexible instrument utilization. Cross-training staff can further reduce disruption during periods of unusually high respiratory testing demand.

Sources: WHO RSV fact sheet; CDC RSV testing and surveillance guidance; Roche Diagnostics; Cepheid.

RSV Diagnostics Market Segmentation by Type

Report Segmentation
By Type

The Type dimension separates recurring assay consumables from instrument purchases and supporting products. The seasonal pattern of RSV transmission creates repeat demand for cartridges and antigen kits, while instruments are purchased less frequently and can be shared with other respiratory tests. Revenue is assigned to the RSV-specific use of multipathogen platforms.

Leading Product

Kits and Assays

Kits and Assays represented an estimated ~74% of 2026 revenue. Molecular cartridges, antigen strips, controls and sample-processing reagents recur with each diagnostic procedure. Hospitals value reliable supply during winter outbreaks, while reference laboratories purchase high-throughput reagents for centralized testing. This recurring-use structure gives consumables a larger revenue contribution than capital equipment.

Installed Base

Instruments

Instrument revenue includes the RSV-attributable allocation of PCR analyzers, immunoassay readers and associated systems. Roche cobas Liat, Cepheid GeneXpert and QuidelOrtho Sofia platforms demonstrate the range of instrument formats. Shared multipathogen use lowers the share attributable to RSV alone, while placements support subsequent reagent purchases.

The remaining Other category captures eligible supporting diagnostic products that do not fit assay or instrument definitions. Manufacturers with established installed bases can compete on turnaround time, reagent pricing and availability during the peak respiratory season. A shift to multiplex panels may change cartridge value without proportionately changing the number of dedicated RSV tests. Supplier contracts and test shelf life further affect procurement decisions.

RSV Diagnostics Market Segmentation by Application

Report Segmentation
By Application

Application classifies the customer using RSV diagnostic products, distinguishing hospital and clinic testing from clinical laboratory services and other institutional demand. Emergency departments and pediatric units often require immediate results for infection control, while reference laboratories handle batched specimens and complex panels. Allocation is based on test revenue by purchasing customer rather than the age of the patient.

Largest Application

Hospitals and Clinics

Hospitals and Clinics represented an estimated ~55% of 2026 revenue. Infants with bronchiolitis and older adults with acute respiratory symptoms often present in hospital settings, where rapid diagnosis helps with patient placement and management. On-site molecular testing can support timely decisions, while antigen assays remain available for selected pediatric pathways.

Laboratory Testing

Clinical Laboratories

Clinical laboratories process respiratory specimens from outpatient practices, hospitals and public-health programs. Centralized platforms can provide higher throughput and multiplex coverage, although sample transportation adds time. Laboratories choose testing algorithms based on assay sensitivity, local reimbursement, staffing and instrument availability. Their role is particularly important when a negative antigen result requires molecular confirmation.

Other applications include surveillance programs and institutional testing outside routine acute care. Clinical protocols differ between countries, and testing volume cannot be inferred directly from infection incidence. The commercial mix is shaped by laboratory networks, specimen routing and reimbursement for multiplex respiratory panels. Provider networks also influence where specimens are collected and processed.

RSV Diagnostics Market Segmentation by Testing Technology

Report Segmentation
By Testing Technology

The technology dimension compares molecular nucleic acid amplification with rapid antigen immunoassays and legacy methods. CDC clinical guidance identifies NAAT as highly sensitive and notes that antigen tests are generally less sensitive. Selection therefore depends on clinical setting, age, specimen type, speed, and affordability rather than a single universal performance measure.

Leading Technology

Molecular NAAT

Molecular NAAT is modeled as the largest technology category in 2026 because multiplex PCR platforms can identify RSV alongside influenza and SARS-CoV-2 with high analytical sensitivity. Roche and Cepheid provide rapid near-patient workflows, while larger laboratories use molecular respiratory panels. Instrument costs are offset by recurring use across multiple respiratory pathogens.

Rapid Alternative

Rapid Antigen Immunoassay

Rapid antigen assays offer comparatively simple workflows and can be useful in pediatric care when used within their labeled indications. Abbott BinaxNOW and QuidelOrtho Sofia RSV FIA illustrate lateral-flow and fluorescence-based approaches. Lower sensitivity in some populations, particularly adults, may lead clinicians to order molecular confirmation for negative results when clinical suspicion remains high.

Viral culture and other methods form a smaller residual category, primarily relevant to specialized laboratory or research needs. Molecular workflows are likely to gain revenue share where clinical systems prioritize multiplex differentiation and rapid results. Antigen testing retains cost and convenience advantages in appropriately selected settings. Laboratories must consider age-specific assay indications when choosing between molecular and antigen testing.

RSV Diagnostics Market Segmentation by Care Setting

Report Segmentation
By Care Setting

Care Setting groups diagnostic revenue by the physical environment in which RSV tests are delivered. Hospital-based laboratories handle inpatient and emergency demand, outpatient sites prioritize fast decisions, reference laboratories process larger volumes, and public-health networks support surveillance. These channels differ in staffing, instrument access, reimbursement and seasonal purchasing patterns.

Acute-Care Testing

Hospital-Based

Hospital-based testing is the leading care-setting category in the analytical model. Severe RSV disease among infants and vulnerable older adults creates a need for rapid pathogen identification and infection-control decisions. Hospitals use both central laboratories and near-patient molecular instruments, with testing demand concentrated around seasonal respiratory surges.

Distributed Testing

Outpatient and Urgent Care

Outpatient and urgent-care sites favor compact instruments and assays that deliver actionable results within the visit. Rapid antigen products may suit selected pediatric cases, while near-patient PCR provides additional sensitivity and multiplex differentiation. Reference laboratories serve clinics without on-site testing, and public-health programs use standardized molecular assays to monitor circulation and inform prevention strategies.

Procurement models increasingly emphasize flexible respiratory menus that keep instruments useful outside RSV season. The resulting mix depends on patient routing, the local availability of molecular testing, and the relative cost of in-house versus outsourced laboratory services. Seasonal staffing constraints also influence test-site selection and the speed of results. Shared instruments support capacity during periods of overlapping influenza and RSV activity.

RSV Diagnostics Market Regional Analysis

Regional RSV diagnostic revenue reflects testing capacity, health-system reimbursement, seasonal disease burden, surveillance funding and the installed base of antigen and molecular platforms. North America leads the modeled 2026 revenue allocation, while Asia-Pacific has substantial unmet testing demand and growing molecular laboratory capacity.

North America

Largest region - ~39% of 2026 global revenue

North America represented an estimated ~39% of global revenue in 2026. The United States has broad access to molecular diagnostic platforms and an established clinical laboratory network, while CDC surveillance supports awareness of seasonal RSV circulation. Hospital emergency departments, pediatric clinics and reference laboratories purchase antigen assays and molecular panels for acute respiratory testing. Molecular differentiation from influenza and SARS-CoV-2 supports use of multiplex cartridges. Procurement concentrates around seasonal respiratory surges, but broad instrument menus allow equipment to be used throughout the year. Canada has comparable clinical needs, with diagnostic purchasing influenced by provincial funding and laboratory consolidation. Across the region, reimbursement policies and institutional procurement determine how much testing shifts from standalone antigen assays to molecular panels. New preventive immunization programs may reduce some severe infections but also increase demand for laboratory surveillance of respiratory disease trends.

Priority country signals

United States

Selected market signal

CDC updated its clinical guidance for RSV diagnostic testing in February 2026 and its surveillance guidance the same month. Molecular NAATs are identified as highly sensitive, while antigen assays are generally less sensitive. Clinical laboratories and emergency departments use these recommendations alongside product labeling to select tests and interpret negative results.

Source: CDC.

Canada

Selected market signal

Provincial laboratory systems purchase RSV diagnostics for hospital and outpatient respiratory care. Winter seasonality influences cartridge inventory, while multiplex molecular testing can help distinguish RSV from influenza in patients with overlapping symptoms. The country is modeled within North America rather than assigned an independently observed share. Provincial test utilization also reflects local respiratory-season surveillance and hospital laboratory capacity.

Source: WHO.

Europe

Established testing - Hospital laboratory networks

European RSV testing is supported by hospital laboratories, public-health surveillance and established molecular diagnostics suppliers. National reimbursement and procurement policies vary, so access to rapid near-patient PCR differs between countries. Respiratory-season demand supports combined influenza and RSV testing, particularly for infants and vulnerable older adults. Laboratories use clinical algorithms to determine when a rapid antigen result requires confirmation. European buyers evaluate sensitivity, turnaround time, instrument compatibility and cartridge cost. Cross-border surveillance programs and clinical research can expand molecular capacity, while budget constraints encourage shared respiratory testing platforms. Preventive RSV immunization programs may change future hospitalization patterns, but they do not eliminate the need to diagnose acute respiratory infections. The region is modeled as a substantial market, with value concentrated in higher-income health systems and centralized laboratory procurement.

Priority country signals

Germany

Selected market signal

Hospital laboratories and outpatient providers use respiratory molecular and antigen diagnostics within national reimbursement and procurement systems. Multiplex panels can improve pathogen differentiation during winter peaks, while instrument placement and consumable contracts influence commercial demand. Procurement teams also assess assay performance by specimen type and patient age. Hospitals weigh multiplex instrument utilization against consumable cost and staffing requirements.

Source: Roche.

United Kingdom

Selected market signal

NHS respiratory testing follows clinical and infection-control needs, with hospital laboratories and surveillance programs providing much of the infrastructure. RSV testing demand is particularly relevant for pediatric admissions and older adults with serious respiratory symptoms. Multiplex assays can help clinical teams distinguish pathogens with similar symptoms and coordinate patient placement.

Source: WHO.

Asia-Pacific

Capacity expansion - Molecular laboratory investment

Asia-Pacific combines mature diagnostic markets in Japan and Australia with large populations and uneven testing access across emerging economies. Demand is influenced by pediatric respiratory admissions, surveillance investment and the expansion of molecular laboratory infrastructure. In higher-income markets, multiplex assays are used to distinguish RSV from influenza and other pathogens. In lower-resource settings, antigen tests may remain important because of cost and limited instrument access. WHO has emphasized RSV surveillance capacity and burden estimation in lower- and middle-income countries, which can improve demand visibility for diagnostic suppliers. Market growth depends on affordable cartridges, laboratory training, reliable supply chains and reimbursement rather than infection burden alone. Regional share is modeled from the global revenue base and does not imply uniform testing coverage across countries. Local diagnostic availability also depends on the organization of pediatric referral pathways.

Priority country signals

China

Selected market signal

Large hospital systems and laboratory networks support respiratory testing, while procurement prices and regional disparities affect molecular assay adoption. Seasonal outbreaks create recurring demand for RSV testing in pediatric care and surveillance programs. Regional procurement and laboratory staffing influence access to near-patient molecular assays, while centralized platforms serve higher-volume hospitals.

Source: WHO.

India

Selected market signal

RSV diagnostic use spans tertiary hospitals, private laboratories and lower-cost testing channels. Expansion depends on affordable molecular platforms and trained personnel, especially outside major cities. Surveillance investment can improve recognition of disease burden and testing needs. Cost per result, supply reliability and instrument maintenance remain key barriers to wider molecular testing access in smaller health facilities.

Source: WHO.

Latin America

Developing market - Variable testing access

Latin American RSV diagnostics demand is concentrated in hospital systems, urban reference laboratories and public-health programs. Pediatric lower respiratory infections create a clinical need for pathogen identification, but molecular testing access varies with reimbursement and laboratory infrastructure. Rapid antigen tests offer an alternative where sophisticated equipment is unavailable, while larger hospitals increasingly use multiplex respiratory panels. Procurement budgets, imported cartridge costs and seasonal inventory management can limit adoption. Regional surveillance initiatives may strengthen the evidence base for testing and prevention policy. Suppliers with flexible instruments and reliable distribution are positioned to serve both private laboratories and public hospitals. The modeled regional allocation reflects commercial diagnostic revenue rather than the full number of RSV infections, which is likely to be undercounted where testing access is limited. Health-system investments in diagnostic training can improve consistency of reporting.

Priority country signals

Brazil

Selected market signal

Brazilian public and private hospitals use RSV diagnostics to support pediatric respiratory care and seasonal surveillance. Molecular testing access is strongest in major laboratory networks, while costs and distribution shape adoption in smaller facilities. Test selection depends on the age and clinical presentation of patients, and negative antigen results may need molecular confirmation.

Source: WHO.

Mexico

Selected market signal

Hospitals and clinical laboratories purchase RSV assays within broader respiratory testing programs. Demand is shaped by winter infection patterns, procurement budgets and the availability of multiplex molecular instruments. Testing programs also rely on trained staff, validated sample collection and dependable supplies during respiratory surges. Clinical laboratories may send complex respiratory specimens to reference centers for molecular testing.

Source: CDC.

Middle East & Africa

Unmet testing need - Surveillance expansion

Middle East and Africa contains highly varied health systems, from advanced tertiary hospitals with molecular platforms to regions where laboratory access remains limited. WHO estimates that most pediatric RSV deaths occur in low- and middle-income countries, which is relevant to diagnostic access and hospital testing capacity. Clinical demand is greatest in infant respiratory admissions and vulnerable patient groups. Molecular assays offer sensitivity and multiplex differentiation, but equipment, electricity, training and cartridge costs can constrain adoption. Rapid antigen products may provide practical testing options when appropriately indicated. Surveillance initiatives in African countries are intended to improve disease-burden estimation and support prevention policy. Commercial revenue remains smaller than the underlying clinical need because many infections are never laboratory confirmed. WHO surveillance efforts help build laboratory standards and improve access to reliable case detection. Regional growth depends on public procurement, international support and sustainable diagnostic supply chains.

Priority country signals

South Africa

Selected market signal

Public and private laboratories perform respiratory pathogen testing, with molecular capacity concentrated in larger centers. RSV surveillance and pediatric hospital demand support assay utilization, while price and transport affect access outside urban areas. Surveillance data can help laboratories anticipate seasonal demand, while expanded molecular capacity supports more accurate RSV detection in high-risk groups.

Source: WHO.

United Arab Emirates

Selected market signal

Large hospitals can use multiplex molecular diagnostics for rapid respiratory differentiation. Purchasing decisions emphasize instrument integration, turnaround time and clinical performance, with demand influenced by hospital patient mix. Hospital laboratories may choose panels that detect influenza and RSV together to streamline workflows and avoid multiple specimen collections. Hospitals with multiplex instruments can distinguish RSV from influenza in one molecular workflow.

Source: Roche.

Competitive Landscape

The RSV diagnostics market includes established multinational diagnostic suppliers and specialized assay manufacturers. Competition spans antigen kits, near-patient molecular analyzers, high-throughput respiratory panels and supporting reagents. Buyers compare analytical performance, approved specimen types, time to result, cartridge pricing and the ability to use installed instruments throughout the respiratory season.

Molecular Point of Care

Roche and Cepheid

Roche cobas Liat and Cepheid Xpert Xpress Flu/RSV demonstrate rapid molecular differentiation of RSV and influenza. Their commercial position depends on installed analyzer networks, recurring cartridge orders and the clinical value of high sensitivity.

Rapid Antigen Testing

Abbott and QuidelOrtho

Abbott BinaxNOW RSV and QuidelOrtho Sofia RSV FIA provide antigen detection formats suited to labeled clinical settings. Their competitive strengths include ease of use and rapid turnaround, while age-specific sensitivity and the need for molecular confirmation in some cases remain important limitations.

Laboratory Molecular Panels

bioM - rieux, Hologic and DiaSorin

Large laboratories purchase multiplex respiratory diagnostics that can include RSV alongside other pathogens. Supplier differentiation depends on assay breadth, throughput, quality controls and integration with laboratory information systems. The modeled RSV revenue excludes non-RSV targets in multipathogen panels.

Broader Diagnostic Supply

BD, Thermo Fisher and Sekisui

Broad diagnostic companies supply molecular workflows, rapid testing products and supporting laboratory infrastructure. Procurement is influenced by regulatory clearances, validated specimens, instrument compatibility and availability of consumables during seasonal respiratory peaks.

Competition is increasingly based on complete diagnostic workflows rather than isolated test sensitivity. Hospitals seek assays that can distinguish RSV from influenza and SARS-CoV-2 using a familiar instrument platform, while outpatient sites place a premium on compact analyzers and fast results. Supplier contracts often combine instruments, reagents, service and training, making installed-base retention important.

Market share is difficult to infer from respiratory-panel revenue because multiplex tests detect several pathogens. The analysis allocates only the RSV-attributable value of these assays, excluding other respiratory targets and vaccine-related spending. FDA-authorized test claims differ by assay, specimen and patient population. Companies with reliable cartridge supply and flexible test menus can better manage the uneven demand caused by RSV seasonality. Regulatory authorization and specimen-specific validation remain necessary before products are used clinically.

Key Companies Profiled

  • Abbott Laboratories
  • bioM - rieux SA
  • F. Hoffmann-La Roche Ltd
  • Becton, Dickinson and Company
  • Thermo Fisher Scientific Inc.
  • Danaher Corporation (Cepheid)
  • QuidelOrtho Corporation
  • Sekisui Diagnostics
  • Hologic Inc.
  • DiaSorin (Luminex)
  • Meridian Bioscience

Recent Developments in the RSV Diagnostics Market

September 2026: WHO prequalified a multi-dose vial presentation of maternal RSV vaccine RSVpreF. Although this is a prevention development rather than a diagnostic product launch, it changes the surveillance environment and reinforces the need to measure RSV burden and immunization impact through laboratory-confirmed surveillance. WHO described the multi-dose presentation as a way to make maternal immunization easier to deliver through national programs. Source

April 2026: CDC updated guidance on multiplex testing for influenza, SARS-CoV-2 and RSV, explaining how molecular tests help differentiate respiratory infections with similar symptoms. The guidance supports the clinical rationale for multipathogen testing workflows in outpatient and hospital settings. CDC also notes that molecular multiplex assays generally offer higher sensitivity than antigen assays for respiratory virus detection. Source

February 2026: CDC updated its RSV diagnostic-testing guidance, describing NAAT methods as highly sensitive and antigen methods as generally less sensitive. This distinction is relevant to product selection, clinical interpretation and confirmatory testing in patients whose symptoms remain suspicious after a negative antigen result. The guidance emphasizes interpreting results alongside clinical history, specimen type and assay-specific instructions. Source

December 2025: WHO published an RSV fact sheet documenting more than 3.6 million annual pediatric hospitalizations worldwide. The updated burden evidence reinforces the role of diagnostic capacity and surveillance, particularly for severe infant disease in resource-limited health systems. The fact sheet identifies infants and older adults as groups at higher risk of severe RSV outcomes. Source

September 2025: WHO convened a meeting focused on strengthening RSV surveillance and disease-burden estimation in sub-Saharan Africa and South and Southeast Asia. The program highlights laboratory capacity building and the need for standardized testing data to guide prevention policy. The WHO initiative uses established respiratory surveillance networks to strengthen burden estimation and laboratory practices. Source

March 2025: WHO described enhanced RSV surveillance in Mongolia, including laboratory training and improved sentinel-site practices. Such programs support more consistent laboratory confirmation and can strengthen the evidence base for national diagnostic procurement and respiratory disease monitoring. WHO described training sessions for sentinel staff as part of the surveillance expansion. Source

Market Outlook, 2027–2036

The RSV diagnostics market is estimated at USD 1.0 billion in 2027 and projected to reach USD 2.0 billion by 2036, representing an 8.0% CAGR over 2027–2036. Growth reflects wider molecular testing, respiratory multiplex adoption and improving surveillance capacity.

Forecast Variable2026 BaselineExpected Effect Through 2036
Global revenueUSD 927.1 millionGrowth toward USD 2.0 billion by 2036
Molecular testingRapid NAAT and multiplex assaysWider access to sensitive pathogen differentiation
Rapid antigen testingSimple near-patient workflowsContinued use in labeled pediatric settings
SurveillanceWHO and CDC RSV monitoringImproved seasonal testing demand visibility
Regional accessUneven molecular laboratory coverageGradual expansion in emerging health systems
SeasonalityWinter respiratory demand peaksInventory and staffing remain operational constraints

Multiplex molecular assays should gain a larger share of RSV diagnostic spending as hospitals seek reliable differentiation among respiratory pathogens. Near-patient PCR can shorten the delay between specimen collection and clinical decisions, while central laboratories retain an important role in higher-throughput testing. Standalone antigen assays will continue where their clinical performance and low cost meet local needs.

North America and Europe benefit from established laboratory networks and instrument placements, while Asia-Pacific, Latin America and parts of Africa offer longer-term opportunities as testing capacity improves. Disease burden alone does not translate directly into revenue; access depends on procurement budgets, trained staff, test availability and reimbursement.

Preventive vaccines and monoclonal antibodies may reduce severe RSV disease in some populations, potentially moderating certain hospital-testing volumes. At the same time, surveillance and vaccine-effectiveness assessment rely on laboratory-confirmed infection data. The forecast therefore distinguishes prevention spending from diagnostics and treats their interaction as a source of uncertainty rather than automatic incremental sales.

Key forecast risks include seasonal variability, lower-than-expected molecular adoption, cartridge price competition and changing reimbursement rules. Upside could arise from wider multiplex adoption, improved point-of-care instrument access and public-health surveillance investment. Supplier differentiation is expected to center on assay sensitivity, validated specimens, instrument compatibility and reliable seasonal supply. CDC surveillance identifies RSV seasonal onset and peak periods using PCR positivity, making public data useful for hospital procurement planning. CDC also publishes RSV seasonality and hospitalization surveillance, helping clinical laboratories anticipate changes in diagnostic demand.

Report Coverage

The study covers RSV-specific diagnostic revenue across products, technology, care settings and regions, excluding vaccine and therapeutic spending.

Market Sizing & Forecasting2026 base year, 2027 estimate, 2036 forecast and CAGR over 2027–2036.
Product SegmentationKits and Assays, Instruments and Other products.
Clinical ApplicationsHospitals and Clinics, Clinical Laboratories and Other purchasers.
Technology AssessmentMolecular NAAT, rapid antigen immunoassays and other methods.
Geographic CoverageFive regions and selected national testing-system characteristics.
Competitive and Regulatory ReviewSupplier platforms, test workflows, clinical guidance and dated developments.

Frequently Asked Questions

What is the size of the RSV diagnostics market?

Global RSV diagnostics revenue is modeled at USD 927.1 million in 2026, estimated at USD 1.0 billion in 2027 and projected to reach USD 2.0 billion in 2036. These figures use the publisher market endpoints normalized to the 2026–2036 framework.

What CAGR is forecast for RSV diagnostics?

The market is projected to grow at an 8.0% CAGR during 2027–2036. The rate is based on normalized publisher revenue endpoints and differs from the publisher stated 9.4% for its earlier forecast framework. Market forecasts reflect commercial testing revenue, not vaccine sales or total RSV disease burden.

Which region leads RSV diagnostics revenue?

North America is modeled as the largest region with an estimated ~39% share of global 2026 revenue. Its diagnostic laboratory networks and molecular instrument base support commercial demand. The regional allocation is a modeled estimate rather than a directly published supplier market share.

Which RSV diagnostic product type is largest?

Kits and Assays represented an estimated ~74% of 2026 revenue. Recurrent purchases of assay cartridges, reagents and antigen test kits support this modeled product leadership. Instruments form a smaller revenue pool because analyzers are purchased less often than test consumables.

Which application generates the most RSV diagnostic revenue?

Hospitals and Clinics represented an estimated ~55% of 2026 revenue, supported by acute respiratory testing, pediatric admissions and infection-control requirements. Clinical laboratories represent another major channel for testing specimens from hospitals and outpatient practices. CDC surveillance shows RSV typically peaks in winter in most of the United States.

What tests are used to diagnose RSV?

Clinical tests include molecular nucleic acid amplification assays such as RT-PCR and rapid antigen detection tests. CDC notes that molecular methods are highly sensitive and antigen tests are generally less sensitive. The most appropriate test depends on patient age, specimen collection and the clinical setting.

Are multiplex respiratory tests used for RSV?

Yes. Multiplex molecular tests can identify RSV alongside influenza and SARS-CoV-2. The RSV market estimate excludes value attributable to other pathogens in multipathogen panels. CDC guidance explains that these tests can inform clinical decisions for patients with overlapping respiratory symptoms.

Who are leading RSV diagnostic suppliers?

Suppliers include Abbott, Roche, Cepheid, QuidelOrtho, bioM - rieux, Hologic, BD, Thermo Fisher Scientific, DiaSorin and Sekisui Diagnostics. Their offerings span rapid antigen tests, molecular assays and respiratory panels. Their commercial roles vary by assay technology, geographic market and regulatory authorization.

What drives demand for RSV testing?

Severe respiratory disease among infants and vulnerable older adults, overlapping symptoms with other viruses, and clinical surveillance requirements support diagnostic testing. WHO reports more than 3.6 million RSV-associated pediatric hospitalizations globally each year. The CDC describes annual seasonal circulation patterns.

What are barriers to wider RSV diagnostic testing?

Barriers include molecular instrument cost, reagent availability, laboratory staffing, reimbursement constraints and the lower sensitivity of some antigen tests. The CDC recommends attention to assay-specific performance and specimen instructions when interpreting results. CDC identifies molecular NAAT assays as highly sensitive for RSV detection.

How do RSV vaccines affect diagnostics demand?

Preventive products may reduce severe RSV disease and some hospital testing, but surveillance and effectiveness monitoring still require laboratory confirmation. Monitoring the impact of immunization programs may increase the need for standardized RSV surveillance and laboratory confirmation.

What is the outlook through 2036?

Molecular multiplex testing and improved surveillance infrastructure are expected to support growth through 2036. Revenue remains sensitive to seasonal outbreaks, product pricing and access to testing infrastructure. Diagnostic purchasing will also depend on reimbursement, seasonal disease circulation and laboratory capacity.

Research Sources & Evidence Base

View research sources used for this overview
Trusted collaboration

Supporting teams across the life-sciences ecosystem

Focused market intelligence for commercial, strategy, product, and research teams across healthcare and life sciences.

Bain
Deloitte
PwC
Commercial Healthcare Partners
Client logo
Client logo
Life-sciences market focus Clear scope and sample review Confidential enquiry support

Display logos only where use is approved. A logo does not imply a public endorsement.

Client feedback

What teams value in their research experience

Feedback from research engagements, with client identities omitted where confidentiality applies.

Publish named testimonials only when the individual and organization have approved disclosure.

Research transparency

Built on a clearly defined research framework

Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.

Defined Market Scope

Coverage, segmentation, geography, and market boundaries are stated within the report.

Evidence-Led Overview

Readers can review the published sources and evidence referenced in this market overview.

Forecast Context

Base, estimated, and forecast years are shown to place the market outlook in context.

Current Publication Record

Each overview displays its report identifier and latest update date.

Report ID 24LS-9340
Base Year 2026
Forecast Period 2026–2036
Last Updated 16 Nov 2026
Inside the full report

What you can explore in this market report

A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.

01

Market Sizing & Forecasts

Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.

02

Segmentation Analysis

Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.

03

Regional Market View

Assess regional performance, selected country context, and factors shaping adoption across major markets.

04

Competition & Developments

Explore company profiles, market positioning, and selected developments relevant to the market landscape.

05

Market Dynamics & Trends

Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.

06

Research Methodology & Sources

Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.